

Infective Endocarditis

Dr. Hala Altarawneh

Bachelor degree in Medicine and Surgery - Mutah university

MSC Medical Microbiology - University of Manchester

PhD Medical Microbiology - University of Manchester



Outline

1. Introduction
2. Pathogenesis & risk factors
3. Classification systems
4. Microbial Etiology
5. Clinical presentation
6. Diagnosis and management

What is Infective Endocarditis?

- Infective endocarditis (IE) is **a microbial infection** of the inner lining of the heart (**endocardium**), most commonly affecting the heart valves.
- **Epidemiology:**
 - Incidence: 11–15 cases per 100,000 persons per year
 - Mean age: 60.8 years (> 50% are > 50 years of age)
 - 3 times more common in men

Risk Factors

- **Cardiac Risk Factors:**

- Rheumatic heart disease
- Valvular abnormalities, Congenital defects
- Presence of a prosthetic valve
- Previous history of endocarditis


- **Patient Risk Factors:**

- Age > 60 years
- IV drug use (most commonly affects the tricuspid valve)
- Poor dentition
- Immunosuppression

- **Iatrogenic Risk Factors** → Implanted devices or catheters

Infective endocarditis: Pathophysiology

- Infective endocarditis: Predisposing factors:
 - Endocardial abnormality or injury
 - Bacteraemia
- Damaged endothelium → platelet and fibrin deposition → adherence by microorganisms
- Proliferation and invasion by organisms → inflammation → vegetation development → valve destruction
- Release of septic emboli → embolic complications and/or metastatic infection



Activated platelet
 Bacterium
 Proteins (e.g. fibrin)
 Endothelial cell
 Subendothelial matrix

Classification: By clinical course

Infective endocarditis can be further classified based on the

- Clinical course
- Type of valve
- Location

Classification: By clinical course

Acute infectious endocarditis:

- **Onset and Progression:** More sudden onset of symptoms → Progresses more rapidly → Fatal if not treated promptly
- **Vegetations:** Larger vegetations
- **Organism virulence:** HIGH (aggressive pathogens) → More commonly affects normal valves
- Most common cause is *S. aureus*
- Other causes include *Streptococcus pneumoniae*, *Streptococcus pyogenes* (Group A Strep)

Classification: By clinical course

Subacute infectious endocarditis:

- More gradual onset of symptoms → Progresses more slowly (weeks to months) → Patients may survive for months untreated.
- Smaller vegetations
- Organism virulence: LOW to MODERATE → More commonly affects congenitally abnormal or diseased valves
- Most common cause is *S. viridans*.

Classification: By clinical course

Chronic infectious endocarditis:

- **Onset:** Months to years
- **Organism virulence:** Very low, intracellular
- **Typical Organisms:** *Coxiella burnetii*, *Bartonella* species

Classification: By valve type

Native valve endocarditis:

- Accounts for 78% of cases
- Further subdivided into:
 - Community acquired (most common)
 - Healthcare associated
 - IV drug use
- Most often associated with: Staphylococcus, Streptococcus, and HACEK organisms

Classification: By valve type

Prosthetic valve endocarditis:

- Early:
 - < 60 days after valve placement
 - Often from contamination during surgery
- Intermediate: 60–365 days after valve placement
- Late:
 - > 1 year after valve placement
 - Usually involves similar organisms to native valve endocarditis
 - Associated with a higher risk of complications and mortality

Classification: By location

Left-sided endocarditis:

- Left-Sided IE is more common:
 - More turbulent flow → more shear stress on valves → more endothelial microtrauma
 - Most pre-existing valve abnormalities affect the left side
- Mitral valve > Aortic valve
- Complications: Left-sided IE leads to **systemic emboli**
 - Brain → Stroke
 - Kidneys → Renal infarcts, glomerulonephritis

Classification: By location

Right-sided endocarditis

(most common in IV drug use):

- Tricuspid valve (90%) > Pulmonic valve (10%)
- Right-sided IE risk factors:
 - IV drug use – 70-80% of right-sided IE occurs in IV drug users
 - Indwelling venous catheters (central lines)
- Complications: Right-sided IE leads to **pulmonary emboli** (not systemic)

Infective Endocarditis Etiology: Staphylococci

General features:

- Gram stain: Gram-positive cocci in clusters ("grape-like")
- Non-motile, non-spore forming
- Facultative anaerobe
- Catalase positive: differentiates from Streptococcus

A. *Staphylococcus aureus* (most common)

- Coagulase positive: differentiates from CoNS
- β -haemolytic (complete haemolysis)

B. Coagulase-negative staphylococci (cons)

- Main Species: *Staphylococcus epidermidis*
- Coagulase negative
- Non-hemolytic or weakly hemolytic

Infective Endocarditis Etiology: Streptococci

General features:

- Gram-positive cocci in CHAINS or PAIRS
- Non-motile, non-spore forming
- Catalase negative

Viridans group streptococci

- **α -haemolytic** (partial haemolysis)
- Optochin Resistant: Differentiates from *S. pneumoniae* (sensitive)
- Bile solubility: Negative → Differentiates from *S. pneumoniae* (positive)

Infective Endocarditis Etiology: HACEK Group

HACEK organisms – a group of fastidious gram-negative bacteria that cause about 5% of IE cases.

HACEK Acronym:

- **H:** *Haemophilus parainfluenzae*, *H. aphrophilus*
- **A:** *Aggregatibacter (Actinobacillus) actinomycetemcomitans*
- **C:** *Cardiobacterium hominis*
- **E:** *Eikenella corrodens*
- **K:** *Kingella kingae*

Clinical Presentation: General signs and symptoms

- Presentation and course depend on the etiology, location of vegetations, and severity.
- **Fever:** (endocarditis should be suspected in a patient with a fever of unknown origin)
- Night sweats
- Fatigue
- Loss of appetite
- Weight loss
- Myalgias and arthralgias

Clinical Presentation: Cardiac findings

- **New or changed cardiac murmur:**
 - Mitral regurgitation, Tricuspid regurgitation, Aortic regurgitation
- **Tachycardia**
- **Arrhythmia:**
 - Potentially due to spread of the infection
 - Results in disruption of the atrioventricular conduction system → conduction delay or heart block


Clinical Presentation: Extracardiac Findings

- **Osler nodes:**
 - Painful red nodules on pads of the fingers and toes
 - Due to immune complex deposition and inflammation
- **Janeway lesions:**
 - Small, painless, erythematous lesions on the palms or soles
 - Due to septic emboli and microabscesses




Clinical Presentation: Extracardiac Findings

- **Splinter haemorrhage:**
 - Small areas of red discoloration under the nails
 - Due to micro emboli in capillaries
- **Petechiae:** Small, pinpoint, non-blanching, red-purple spots on the skin or mucous membranes.



Clinical Presentation: Extracardiac Findings

- **Roth spots:**
 - Red spots with pale centers on fundoscopic exam
 - Due to retinal haemorrhages
- **Conjunctiva haemorrhage**



Splinter hemorrhages



Janeway lesions (painless spots on palms/soles of feet)



Osler's Nodes (painful nodules in pulp of fingers/toes)



Conjunctival hemorrhages

Diagnosis: Duke diagnostic criteria

- The Duke diagnostic criteria is a set of clinical criteria that can aid in the diagnosis of IE.
- Must meet 1 of the following for a definitive diagnosis of IE:
 - 2 major criteria, or 1 major plus 3 minor criteria, or 5 minor criteria
- **Major criteria:**
 - Positive blood cultures (1 of the following):
 - Typical organism for IE in 2 separate blood cultures
 - Findings of endocardial involvement (1 of the following):
 - By echocardiogram
 - New regurgitation murmur

Diagnosis: Duke diagnostic criteria

- **Minor criteria:**

- Fever $> 38^{\circ}\text{C}$
- Risk factors: IV drug use, or Predisposing heart condition
- Vascular findings:
 - Major arterial emboli
 - Janeway lesions
 - Conjunctival haemorrhages
 - Septic infarcts
- Immunologic findings: Osler nodes, Roth spots, Glomerulonephritis
- Microbiologic findings by culture that do not meet major criteria

Management

Antibiotic therapy:

- Prolonged IV therapy: Typically, 4-6 weeks (native valve) or 6-8 weeks (prosthetic valve)
- Bactericidal antibiotics
- Start empiric therapy while waiting for blood culture results, initial therapy typically vancomycin

Surgical management

Valve repair or replacement is indicated for: Heart failure, Persistent infection, Embolic events, Prosthetic valve dehiscence

Thank you